• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Effect of a novel orally bioavailable mGluR5 inhibitor, RG7090, on the metastasis of oral cancer cells

Research Project

Project/Area Number 16K11731
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Surgical dentistry
Research InstitutionEhime University (2019)
Dokkyo Medical University (2016-2018)

Principal Investigator

kuribayashi nobuyuki  愛媛大学, 医学系研究科, 助教 (80617332)

Co-Investigator(Kenkyū-buntansha) 木内 誠  獨協医科大学, 医学部, 助教 (00759483)
内田 大亮  獨協医科大学, 医学部, 准教授 (20335798)
川又 均  獨協医科大学, 医学部, 教授 (70224847)
Project Period (FY) 2016-04-01 – 2020-03-31
Project Status Completed (Fiscal Year 2019)
Budget Amount *help
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
KeywordsmGluR 5 / CXCR 4 / mGluR5 / CXCR4 / mGluR5 / 口腔癌 / 歯学 / 腫瘍学
Outline of Final Research Achievements

We could not demonstrate significant results with a novel orally bioavailable mGluR5 inhibitor, RG7090 on the metastasis of oral cancer cells. However, we focus only on minimally invasive and persistent control, continued our study with AMD 070, a novel oral inhibitor of CXCR4 that is upstream of mGluR5. Mice adminstrated with AMD 070 did not exhibit any side effects, such as hematotoxicity, allergic reactions or weight loss. Although treatment with AMD070 did not affect the anchorage-dependent growth of B88-SDF-1 cells, it significantly suppressed the anchorage-independent growth. Moreover, we performed an experimental therapy using AMD070 to prevent the distant metastasis of B88-SDF-1 cells in vivo. Daily oral administration of AMD070 significantly inhibited the lung metastasis of B88-SDF-1 cells in nude mice.

Academic Significance and Societal Importance of the Research Achievements

今回の研究では、mGluR5 特異的経口阻害剤での有意な結果は得られなかったが、その上流の CXCR4 特異的経口阻害剤による転移抑制効果および有害事象について確認し、新規経口害剤が、SDF-1/CXCR4システムを介した口腔癌の転移を、低侵襲かつ持続的に抑制できる可能性を示唆した。

Report

(5 results)
  • 2019 Annual Research Report   Final Research Report ( PDF )
  • 2018 Research-status Report
  • 2017 Research-status Report
  • 2016 Research-status Report
  • Research Products

    (4 results)

All 2019 2018

All Journal Article (2 results) (of which Peer Reviewed: 2 results) Presentation (2 results)

  • [Journal Article] Oral squamous cell carcinoma arising in a patient with werner syndrome: genomic analysis2019

    • Author(s)
      Nobuyuki Kuribayashi, Daisuke Uchida, Yoichiro Hamasaki, Hitoshi Kawamata
    • Journal Title

      International Journal of Oral and Maxillofacial Surgery

      Volume: 48 Issue: 11 Pages: 1394-1394

    • DOI

      10.1016/j.ijom.2019.06.005

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells.2018

    • Author(s)
      Uchida D, Kuribayashi N, Kinouchi M, Sawatani Y, Shimura M, Mori T, Hasegawa T, Miyamoto Y, Kawamata H.
    • Journal Title

      Oncol Rep

      Volume: 40 Pages: 303-308

    • DOI

      10.3892/or.2018.6400

    • Related Report
      2018 Research-status Report
    • Peer Reviewed
  • [Presentation] Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells.2018

    • Author(s)
      Kuribayashi N, Uchida D, Kinouchi M, Kuribayashi K, Hasegawa T, Yagisawa S, Kawamata H:
    • Organizer
      American Association for Cancer Research 107th Annual Meeting
    • Related Report
      2018 Research-status Report
  • [Presentation] 口腔癌の転移における新規経口CXCR4阻害剤AMD070の有効性2018

    • Author(s)
      栗林伸行,木内 誠,内田大亮,川又 均
    • Organizer
      第28回日本口腔内科学会,第31回日本口腔診断学会合同学術学会
    • Related Report
      2018 Research-status Report

URL: 

Published: 2016-04-21   Modified: 2021-02-19  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi